Top Markets
#1 Gravity Gravity +68.84%
#2 Galxe Galxe +41.90%
#3 Aria.AI Aria.AI +26.39%
#4 Audiera Audiera +23.18%
#5 Velas Velas +23.15%
#6 Codatta Codatta +20.32%
#7 Pepe Pepe +18.90%
#8 Derive Derive +18.72%
#9 MemeCore MemeCore +15.75%
#10 Memetern Memetern +15.17%
Coin of the day
Gravity Gravity
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Classifica tra le azioni #157
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Prezzo delle azioni
$469.34
Capitalizzazione di mercato
$119.21B
Variazione (1 giorno)
-1.84%
Variazione (1 anno)
-7.87%
Paese
US
Scambia Vertex Pharmaceuticals Incorporated (VRTX)

Categoria

Healthcare
Capitalizzazione di mercato
Ricavi
altro
Utili
Storico dei prezzi
Rapporto P/E
Rapporto P/S
Rapporto P/B
Margine operativo
EPS
Frazionamenti azionari
Dividendi
Rendimento da dividendi
Azioni in circolazione
Utile per Vertex Pharmaceuticals Incorporated (VRTX)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Vertex Pharmaceuticals Incorporated, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Vertex Pharmaceuticals Incorporated dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -
NL